OGX-011

01/01/2017 - "Prostate cancer: Custirsen fails to improve outcomes."
01/01/2013 - "Potential use of custirsen to treat prostate cancer."
02/15/2010 - "Phase I and II clinical trial data indicate that the second generation ASO, custirsen (OGX-011), has biologic and clinical activity, suppressing sCLU expression in prostate cancer tissues by more than 90%. "
02/01/2019 - "Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC).We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. "
02/01/2019 - "Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer."

11/15/2005 - "Doppler studies showed that tumor blood flow was compromised when mice bearing H460 xenografts were treated with OGX-011 and radiation. "
09/01/2017 - "A population PK model for custirsen was successfully developed in cancer patients and healthy subjects, including covariates contributing to variability in custirsen PK."
09/01/2017 - "This meta-analysis evaluated the population pharmacokinetics (PK) of custirsen in cancer patients and healthy subjects. "
10/01/2012 - "This article describes the mechanism of action and safety profile of OGX-011 and details the Phase I and II results in human solid organ malignancies. "
09/01/2011 - "In vivo evaluation of the Hsp90 inhibitors with OGX-011 in xenograft models of human CRPC showed that OGX-011 markedly potentiated antitumor efficacy, leading to an 80% inhibition of tumor growth with prolonged survival compared with Hsp90 inhibitor monotherapy. "

05/01/2006 - "There have been four kinds of Phase II studies that have begun to further evaluate the efficacy of OGX-011 in patients with prostate, breast and lung cancers."
11/15/2005 - "Apoptosis was significantly increased when H460 lung cancer cells were treated with OGX-011 plus radiation. "
02/01/2008 - "Phase II trials of combined OGX-011 and chemotherapy are ongoing in patients with prostate, breast, and lung cancers."
11/15/2005 - "A combination of radiotherapy and OGX-011 improved control of tumor growth and vascular regression in the H460 lung cancer model."
09/01/2017 - "Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. "

12/01/2006 - "Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer."
01/15/2009 - "The primary objective of this phase II trial was to assess the safety and efficacy of the combination of OGX-011 and docetaxel for metastatic breast cancer. "
01/15/2009 - "Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer."
01/15/2009 - "The combination of OGX-011 and docetaxel at 75 mg/m(2) is well tolerated and clinical activity was seen in these patients with metastatic breast cancer, but there was an insufficient number of responses to meet the criteria for proceeding to the second stage of accrual."
12/01/2005 - "These data identify clusterin as a valid therapeutic target and provides preclinical proof-of-principle to test OGX-011 in multimodality therapies for breast cancer."

02/20/2015 - "CLU suppression using OGX-011 may represent a promising therapeutic option for suppressing HCC metastasis. "
02/20/2015 - "We further observed that CLU knockdown using the CLU inhibitor OGX-011 significantly suppressed HCC metastasis in two metastatic models through inhibiting EIF3I/Akt/MMP13 signaling. "
02/01/2009 - "Furthermore, OGX-011 chemo-sensitized UM-UC-3R cells to gemcitabine in vitro with a reduction in the concentration that reduces the effect by 50% (IC50) from 100 nm to 10 nm. Tumour volume and the incidence of metastasis in nude mice injected with UM-UC-3R cells was significantly greater than those of nude mice injected with UM-UC-3P cells; however, systemic administration of OGX-011 plus a low dose of gemcitabine significantly suppressed tumour volume and the incidence of metastasis in both groups. "